Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will meet (a) NHS England, (b) MHRA and (c) bodies supporting people affected by (i) Post-Finasteride Syndrome and (ii) Post-SSRI Sexual Dysfunction following the use of anti-depressant medication to discuss that issue.

Ministers meet regularly with external stakeholders on a variety of issues, including with organisations such as NHS England, the Medicines and Healthcare products Regulatory Agency (MHRA), and bodies representing patients affected by medicines and medical devices.

The MHRA, as the regulator for medicines and medical devices, ensures that appropriate information is provided for each medicine on the United Kingdom’s market. The MHRA is currently reviewing the existing warnings in relation to sexual dysfunction which may continue after stopping anti-depressant medication, and recently completed an extensive safety review of finasteride and persistent sexual dysfunction, including after stopping treatment with finasteride.